Britain and America have announced a key bilateral deal that will maintain zero import taxes on British drug products being sold in the US market.
Agreement Details of the Deal
Under the terms of the agreement, the UK has committed to boost spending on medicines through the NHS. This pledge secures that tariffs on these crucial products will stay at nothing for a period of three years.
This development comes after recent statements to significantly raise import taxes on branded drug imports, with figures mentioned as high as one hundred percent.
"This agreement between the UK strengthens the worldwide climate for innovative medicines and establishes much-needed fairness to U.S.–U.K. medicine commerce," a statement said.
Trade Importance
Medicines constitute one of the the United Kingdom's most significant exports to the United States, which is by far the biggest destination for major British pharmaceutical firms.
Statistics show that in the one-year period prior to last September, the UK sold pharmaceutical products totaling £11.1bn to the US. This amount made up a significant portion of British export trade in that span.
"This agreement protects jobs, boosts funding and paves the way for the UK to emerge as a worldwide center for life sciences," a minister remarked.
Detailed UK Commitments
The deal includes several specific pledges from the United Kingdom:
- Revised Affordability Limit: The UK will increase the affordability limit at which it judges new treatments to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a target to double total public funding on treatments from 0.3% of Gross Domestic Product to 0.6 percent over the coming ten years.
- Refund Ceiling: The percentage drug companies must refund to the NHS to control costs will be capped at 15%. In the past, refunds exceeded twenty percent.
Broader Context
This agreement follows a protracted row between the pharmaceutical industry and the British authorities over medicine costs and NHS adoption.
The disagreement were exacerbated by arguments that US customers were charged several times more for the equivalent treatments than people in the UK and Europe.
Over the last 18 months, several large drug company projects in the UK have been delayed or scrapped, while multi-billion-dollar funding commitments have been pledged toward US facilities.
One official stated that the NHS must invest a greater share on medicines, noting that its expenditure on drugs had declined as a proportion of its overall budget over the previous ten-year period.
